UBS Group’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

UBS Group’s Portfolio BIOSW Stock Details BIOSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,459	Closed	-$138	–	10545
2023 Q3	$138	Buy	+2,459	New	+$294	﹤0.01%	8807
2023 Q1	–	Sell	-215	Closed	-$2	–	11031
2022 Q4	$2	Buy	215 +115	+115%	+$6	﹤0.01%	10656
2022 Q3	$0	Sell	100 -10,700	-99%	-$1.19K	﹤0.01%	11314
2022 Q2	$2K	Buy	10,800 +100	+0.9%	+$19	﹤0.01%	9696
2022 Q1	$2K	Buy	+10,700	New	+$2.78K	﹤0.01%	9737

UBS Group's BIOSW Position: Q4 2023 in Review

UBS Group sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q4 2023, closing a stake of 2,459 shares — an estimated $138 sold.

UBS Group first reported a position in BIOSW in Q1 2022 and held it in 5 quarters. The position peaked at $2K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOSW as of Q4 2023.

UBS Group reported no remaining BioPlus Acquisition Corp. Warrants position as of Q4 2023 after selling out during the quarter.
UBS Group sold 2,459 BioPlus Acquisition Corp. Warrants shares in Q4 2023, an estimated $138.
UBS Group first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 5 quarters.
UBS Group's BioPlus Acquisition Corp. Warrants position peaked at $2K in Q2 2022.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.